Trial reportNature medicine2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
Abstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 12 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 12 pooled it
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 12 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Pooled it
- PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.Molecular cancer · 2024Pooled it
- Pooled it
- Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.Journal of the American Heart Association · 2024Pooled it
- PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.Frontiers in endocrinology · 2023Pooled it
- PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Pooled it
- Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Expanding the PD-L1 Paradigm: A Comprehensive Systematic Review and Meta-Analysis of Scoring Systems and Additional Biomarkers Influencing Immune Checkpoint Inhibitor Outcomes in Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Trial
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.Nature cancer · 2026Trial
- Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.Journal for immunotherapy of cancer · 2024Trial
- Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.Nature communications · 2023Trial
- Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.Nature medicine · 2022Trial
- Trial
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 20 institutions in 2 countries.
Thomas BachelotDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Thomas FilleronDepartment of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.
Ivan BiecheDepartment of Genetics, Institut Curie and Paris-Descartes University, Paris, France.
Monica ArnedosDepartment of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France.
Mario CamponeInstitut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain et Angers, France.
Florence DalencDepartment of Medical Oncology, Institut Claudius-Regaud, IUCT Oncopole and University of Paul Sabatier, Toulouse, France.
Florence CoussyDepartment of Medical Oncology, Institut Curie, Paris, France.
Marie-Paule SablinDepartment of Medical Oncology, Institut Curie, Paris, France.
Marc DebledDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.
Claudia Lefeuvre-PlesseDepartment of Medical Oncology, Centre Eugène Marquis, Rennes, France.
Anthony GoncalvesDepartment of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Marie-Ange Mouret ReynierDepartment of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
William JacotDepartment of Medical Oncology, Institut de Cancérologie de Montpellier, Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194 and Montpellier Université, Montpellier, France.
Benoit YouDepartment of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL); Centre d'Investigation de Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL); Univ Lyon, Université Claude Bernard Lyon 1; EMR UCBL/HCL 3738; GINECO, Lyon, France.
Philippe BarthelemyInstitut de Cancérologie Strasbourg, Strasbourg, France.
Benjamin VerretDepartment of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France.
Nicolas IsambertDepartment of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
Xavier TchiknavorianCentre Hospitalier Intercommunal Toulon La Seyne-sur-Mer, Hôpital Sainte Musse, Toulon, France.
Christelle LevyDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Jean-Christophe TheryDepartment of Medical Oncology, Centre Henri Becquerel, University of Medicine of Rouen, Rouen, France.
Tifenn L'HaridonCentre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.
Jean-Marc FerreroDepartment of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
Alice MegeInstitut Sainte Catherine, Avignon, France.
Francesco Del PianoHôpitaux du Leman, Thonon Les Bains, France.
Etienne RouleauCancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy Cancer Campus, Villejuif, France.
Alicia Tran-DienINSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Julien AdamDepartment of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
Amelie LusqueDepartment of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.
Marta JimenezUnicancer, Paris, France.
Alexandra JacquetUnicancer, Paris, France.ORCID http://orcid.org/0000-0001-6377-2487
Ingrid GarberisINSERM UMR981 and Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Fabrice AndreDepartment of Medical Oncology, Gustave Roussy, Université Paris Saclay, Villejuif, France. fabrice.andre@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-5795-8357
Inserm · FRInstitut Claudius Regaud · FRInstitut Curie · FRUniCancer Group · FRUniversité Paris-Saclay · FRCentre Antoine Lacassagne · FRCentre Eugène Marquis · FRCentre François Baclesse · FRCentre Georges François Leclerc · FRCentre Henri BecquerelCentre Hospitalier Intercommunal Toulon-La Seyne-sur-Mer · FRCentre Jean Perrin · FRCentre Léon Bérard · FRDélégation Paris 5 · FRInstitut Bergonié · FRInstitut de Cancérologie de l'Ouest · FRInstitut de Cancérologie Strasbourg · FRInstitut Gustave Roussy · FRInstitut Paoli-Calmettes · FRInstitut Sainte Catherine · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST IMMUNO substudy included patients with human epidermal growth factor receptor type 2 (Her2)-negative metastatic breast cancer whose disease did not progress after six to eight cycles of chemotherapy. Patients (n = 199) were randomized to either durvalumab (10 mg kg
Indexed as
AdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBreastErb-b2 Receptor Tyrosine KinasesFemaleHumansLung NeoplasmsMaintenance ChemotherapyMiddle AgedNeoplasm MetastasisProgression-Free SurvivalTriple Negative Breast NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humandurvalumabERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.